KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Accounts Payables: 2009-2024

Historic Accounts Payables for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $607.0 million.

  • Biomarin Pharmaceutical's Accounts Payables rose 11.57% to $798.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $798.4 million, marking a year-over-year increase of 11.57%. This contributed to the annual value of $607.0 million for FY2024, which is 11.15% down from last year.
  • As of FY2024, Biomarin Pharmaceutical's Accounts Payables stood at $607.0 million, which was down 11.15% from $683.1 million recorded in FY2023.
  • Biomarin Pharmaceutical's 5-year Accounts Payables high stood at $683.1 million for FY2023, and its period low was $492.5 million during FY2020.
  • Moreover, its 3-year median value for Accounts Payables was $607.0 million (2024), whereas its average is $621.0 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Accounts Payables fell by 13.68% in 2020, and later grew by 19.23% in 2023.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Accounts Payables stood at $492.5 million in 2020, then climbed by 1.16% to $498.3 million in 2021, then increased by 14.99% to $573.0 million in 2022, then rose by 19.23% to $683.1 million in 2023, then declined by 11.15% to $607.0 million in 2024.